MedTrace Logo

Study to Assess VB-201 in Patients With Psoriasis

NCT01001468 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 185

Last updated 2011-11-16

No results posted yet for this study

Summary

The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.

Conditions

  • Active Plaque Psoriasis

Interventions

DRUG

VB-201

Single daily dose of oral VB-201 20 mg

DRUG

VB-201

Single daily dose or oral VB-201 80 mg

OTHER

Placebo

Single daily dose of oral placebo

Sponsors & Collaborators

  • Vascular Biogenics Ltd. operating as VBL Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States
  • Germany
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001468 on ClinicalTrials.gov